leeWT
2021-11-18
Good news
J&J sees potential for 14 new multibillion-dollar drugs by 2025
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":876097273,"tweetId":"876097273","gmtCreate":1637242184934,"gmtModify":1637242185107,"author":{"id":3581563058003710,"idStr":"3581563058003710","authorId":3581563058003710,"authorIdStr":"3581563058003710","name":"leeWT","avatar":"https://static.tigerbbs.com/49e0521f4fb5a74a66948df0eddb1c8b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good news</p></body></html>","htmlText":"<html><head></head><body><p>Good news</p></body></html>","text":"Good news","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/876097273","repostId":1113277554,"repostType":4,"repost":{"id":"1113277554","kind":"news","pubTimestamp":1637241355,"share":"https://www.laohu8.com/m/news/1113277554?lang=&edition=full","pubTime":"2021-11-18 21:15","market":"us","language":"en","title":"J&J sees potential for 14 new multibillion-dollar drugs by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1113277554","media":"Reuters","summary":"Johnson & Johnson(JNJ.N)expects to file for approval of 14 new drugs by 2025, and has projected aver","content":"<p>Johnson & Johnson(JNJ.N)expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company's pharmaceuticals unit on Thursday.</p>\n<p>Among the top pipeline assets, Mathai Mammen, global head of research for J&J's Janssen pharmaceutical division, pointed to a drug combination for non-small cell lung cancer, an anticoagulant it is developing with partner Bristol Myers Squibb(BMY.N)and a vaccine for respiratory syncytial virus (RSV).</p>\n<p>J&J said last week that it plans to spin off its consumer health division that sells Listerine and Band-Aid bandages in order to focus on pharmaceuticals and medical devices in the biggest shakeup in the U.S. company's135-year history.</p>\n<p>Mammen in an interview said he did not think the transaction would change much in terms of research and development spending.</p>\n<p>\"We're really happy and proud of the way R&D is functioning - the strategy we're using and the level of investments,\" he said.</p>\n<p>J&J developed one of the three COVID-19 vaccines authorized in the United States, but its use in the country tailed off sharply after rare cases of blood clotting were linked to the shot.</p>\n<p>Nonetheless, Mammen said J&J still expects to develop more vaccines using the same adenovirus vector technology.</p>\n<p>\"It induces not just antibodies that tend to be relatively short-lived, but also good, multiple kinds of T-cells... so you have that really long-lasting benefit,\" Mammen said.</p>\n<p>Mammen said the company was \"actively looking\" at a lot of different technology platforms, including messenger RNA, the backbone of the COVID-19 vaccines from Moderna(MRNA.O)and Pfizer(PFE.N)and partner BioNTech</p>\n<p>\"We have several technologies right now, and we'll look at expanding that out further,\" he said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J sees potential for 14 new multibillion-dollar drugs by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J sees potential for 14 new multibillion-dollar drugs by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-18 21:15 GMT+8 <a href=https://www.reuters.com/business/healthcare-pharmaceuticals/jj-sees-potential-14-new-multibillion-dollar-drugs-by-2025-2021-11-18/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson(JNJ.N)expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/jj-sees-potential-14-new-multibillion-dollar-drugs-by-2025-2021-11-18/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/jj-sees-potential-14-new-multibillion-dollar-drugs-by-2025-2021-11-18/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113277554","content_text":"Johnson & Johnson(JNJ.N)expects to file for approval of 14 new drugs by 2025, and has projected average peak sales of $4 billion a year for each, a top J&J scientist said ahead of a strategy review of the company's pharmaceuticals unit on Thursday.\nAmong the top pipeline assets, Mathai Mammen, global head of research for J&J's Janssen pharmaceutical division, pointed to a drug combination for non-small cell lung cancer, an anticoagulant it is developing with partner Bristol Myers Squibb(BMY.N)and a vaccine for respiratory syncytial virus (RSV).\nJ&J said last week that it plans to spin off its consumer health division that sells Listerine and Band-Aid bandages in order to focus on pharmaceuticals and medical devices in the biggest shakeup in the U.S. company's135-year history.\nMammen in an interview said he did not think the transaction would change much in terms of research and development spending.\n\"We're really happy and proud of the way R&D is functioning - the strategy we're using and the level of investments,\" he said.\nJ&J developed one of the three COVID-19 vaccines authorized in the United States, but its use in the country tailed off sharply after rare cases of blood clotting were linked to the shot.\nNonetheless, Mammen said J&J still expects to develop more vaccines using the same adenovirus vector technology.\n\"It induces not just antibodies that tend to be relatively short-lived, but also good, multiple kinds of T-cells... so you have that really long-lasting benefit,\" Mammen said.\nMammen said the company was \"actively looking\" at a lot of different technology platforms, including messenger RNA, the backbone of the COVID-19 vaccines from Moderna(MRNA.O)and Pfizer(PFE.N)and partner BioNTech\n\"We have several technologies right now, and we'll look at expanding that out further,\" he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":330,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/876097273"}
精彩评论